[1] HAN B, ZHENG R, ZENG H, et al.Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53.
[2] BRAY F, LAVERSANNE M, SUNG H, et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[3] LEE J S, LEE J S, YUN H J, et al.Prognosis of anaplastic thyroid cancer with distant metastasis[J]. Cancers(Basel), 2022, 14(23):5784.
[4] WOLFF L, STEINDL A, POPOV P, et al.Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer[J]. Clin Exp Metastasis, 2023, 40(3):217-226.
[5] ESMAEILZADEH M, ATALLAH O, MVLLER J A, et al.Brain metastases from thyroid carcinoma:prognostic factors and outcomes[J]. Cancers(Basel), 2024, 16(13):2371-2379.
[6] CHOI J, KIM J W, KEUM Y S, et al.The largest known survival analysis of patients with brain metastasis from thyroid cancer based on prognostic groups[J]. PLoS One, 2016, 11(4):e0154739.
[7] LI C, WU Q, SUN S.Radioactive iodine therapy in patients with thyroid carcinoma with distant metastases:a SEER-based study[J]. Cancer Control, 2020, 27(1):1073274820914661.
[8] SAITO F, URUNO T, SHIBUYA H, et al.Prognosis after brain metastasis from differentiated thyroid carcinoma[J]. World J Surg, 2016, 40(3):574-581.
[9] WU T, JIAO Z, LI Y, et al.Brain metastases from differentiated thyroid carcinoma:a retrospective study of 22 patients[J]. Front Endocrinol(Lausanne), 2021, 12:730025.
[10] PRINZI A, VAN VELSEN E F S, BELFIORE A, et al.Brain metastasis in differentiated thyroid cancer:clinical presentation, diagnosis and management[J]. Thyroid, 2024, 34(10):1194-1204.
[11] 王志宏, 张浩.甲状腺癌远处转移常见部位及影像学检查的应用[J]. 中国实用外科杂志, 2024, 44(6):648-657.
[12] 盛舒言; 胡瑛.脑转移瘤免疫相关疗效评价标准的研究进展[J]. 中国肺癌杂志, 2021, 24(2):124-130.
[13] LIN N U, LEE E Q, AOYAMA H, et al.Response assessment criteria for brain metastases:proposal from the RANO group[J]. Lancet Oncol, 2015, 16(6):e270-e278.
[14] OSBORNE J R, KONDRACIUK J D, RICE S L, et al.Thyroid cancer brain metastasis:survival and genomic characteristics of a large tertiary care cohort[J]. Clin Nucl Med, 2019, 44(7):544-549.
[15] CACHO-DÍAZ B, SPÍNOLA-MAROÑO H, GRANADOS-GARCÍA M, et al.Metástasis cerebrales en pacientes con cáncer de tiroides[J]. Medicina Interna de México, 2017, 33(4):452-458.
[16] 中华人民共和国国家卫生健康委员会医政医管局.甲状腺癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022, 42(12):1343-1357.
[17] HATIBOGLU M A, AKDUR K, SAWAYA R.Neurosurgical management of patients with brain metastasis[J]. Neurosurg Rev, 2020, 43(2):483-495.
[18] KAAL E C, NIL C G, VECHT C J.Therapeutic management of brain metastasis[J]. Lancet Neurol, 2005, 4(5):289-298.
[19] YOO J, KIM H J, KIM S M, et al.Prognostic factors to predict the efficacy of surgical interventions against brain metastasis secondary to thyroid cancer[J]. Eur Thyroid J, 2022, 11(5):e220087.
[20] TAN A C, HEIMBERGER A B, MENZIES A M, et al.Immune checkpoint inhibitors for brain metastases[J]. Curr Oncol Rep, 2017, 19(6):38.
[21] HAUGEN B R, ALEXANDER E K, BIBLE K C, et al.2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
[22] VOGELBAUM M A, BROWN P D, MESSERSMITH H, et al.Treatment for brain metastases:ASCO-SNO-ASTRO Guideline[J]. J Clin Oncol, 2022, 40(5):492-516.
[23] LADBURY C, PENNOCK M, YILMAZ T, et al.Stereotactic radiosurgery in the management of brain metastases:a case-based Radiosurgery Society Practice Guideline[J]. Adv Radiat Oncol, 2024, 9(3):101402.
[24] BUNEVICIUS A, FRIBANCE S, PIKIS S, et al.Stereotactic radiosurgery for differentiated thyroid cancer brain metastases:an international, multicenter study[J]. Thyroid, 2021, 31(8):1244-1252.
[25] BERNAD D M, SPERDUTO P W, SOUHAMI L, et al.Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers[J]. J Neurooncol, 2010, 98(2):249-252.
[26] 张子倩, 李飞龙, 杨琳, 等.伽玛刀联合替莫唑胺治疗肺癌脑转移瘤患者的效果及对无进展生存时间、神经认知功能的影响[J]. 现代医学, 2020, 48(4):443-446.
[27] BYUN J, SONG S W, KIM Y H, et al.Treatment outcome of gamma knife radiosurgery for brain metastasis from thyroid cancer:favorable local control but poor survival[J]. World Neurosurg, 2023, 171:e605-e610.
[28] MITCHELL D K, KWON H J, KUBICA P A, et al.Brain metastases:an update on the multi-disciplinary approach of clinical management[J]. Neurochirurgie, 2022, 68(1):69-85.
[29] SUBBIAH V, HU M I, WIRTH L J, et al.Pralsetinib for patients with advanced or metastaticRET-altered thyroid cancer(ARROW):a multi-cohort, open-label, registrational, phase 1/2 study[J]. Lancet Diabetes Endocrinol, 2021, 9(8):491-501.
[30] WIRTH L J, SHERMAN E, ROBINSON B, et al.Efficacy of selpercatinib in RET-altered thyroid cancers[J]. N Engl J Med, 2020, 383(9):825-835.
[31] DRILON A, SIENA S, OU S-H I, et al.Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib:combined results from two phase I trials(ALKA-372-001 and STARTRK-1)[J]. Cancer Discovery, 2017, 7(4):400-409.
[32] HONG D S, DUBOIS S G, KUMMAR S, et al.Larotrectinib in patients with TRK fusion-positive solid tumours:a pooled analysis of three phase 1/2 clinical trials[J]. Lancet Oncol, 2020, 21(4):531-540.
[33] CHEN X, KANG R, KROEMER G, et al.Broadening horizons:the role of ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021, 18(5):280-296.
[34] WANG X, XU S, ZHANG L, et al.Vitamin C induces ferroptosis in anaplastic thyroid cancer cells by ferritinophagy activation[J]. Biochem Biophys Res Commun, 2021, 551:46-53.
[35] SHI J, WU P, SHENG L, et al.Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma[J]. Cancer Cell International, 2021, 21(1):669-682.
[36] WANG W, GREEN M, CHOI J E, et al.CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy[J]. Nature, 2019, 569(7755):270-274.
[37] SOTTILE R, FEDERICO G, GAROFALO C, et al.Iron and ferritin modulate MHC class I expression and NK cell recognition[J]. Front Immunol, 2019, 10:224.
[38] SONG X, XIE Y, KANG R, et al.FANCD2 protects against bone marrow injury from ferroptosis[J]. Biochem Biophys Res Commun, 2016, 480(3):443-449.
[39] ARVANITIS C D, FERRARO G B, JAIN R K.The blood-brain barrier and blood-tumour barrier in brain tumours and metastases[J]. Nat Rev Cancer, 2020, 20(1):26-41.
[40] MEHRABIAN A, MASHREGHI M, DADPOUR S, et al.Nanocarriers call the last shot in the treatment of brain cancers[J]. Technol Cancer Res Treat, 2022, 21:15330338221080974.
[41] JIANG K, YU Y, QIU W, et al.Protein corona on brain targeted nanocarriers:challenges and prospects[J]. Adv Drug Deliv Rev, 2023, 202:115114.
[42] MENDANHA D, VIEIRA DE CASTRO J, FERREIRA H, et al.Biomimetic and cell-based nanocarriers-new strategies for brain tumor targeting[J]. J Control Release, 2021, 337:482-493.
[43] OH K S, HAN H, YOON B D, et al.Effect of HIFU treatment on tumor targeting efficacy of docetaxel-loaded pluronic nanoparticles[J]. Colloids Surf B Biointerfaces, 2014, 119:137-144.
[44] GAO X, XU J, YAO T, et al.Peptide-decorated nanocarriers penetrating the blood-brain barrier for imaging and therapy of brain diseases[J]. Adv Drug Deliv Rev, 2022, 187:114362.
[45] ASHOKAN A, SARKAR S, KAMRAN M Z, et al.Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites[J]. Proc Natl Acad Sci U S A, 2024, 121(20):e2318119121.
[46] VARRICCHI G, LOFFREDO S, MARONE G, et al.The immune landscape of thyroid cancer in the context of immune checkpoint inhibition[J]. Int J Mol Sci, 2019, 20(16):3934-3941.
[47] PARDOLL D M.The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4):252-264.
[48] OKAZAKI T, CHIKUMA S, IWAI Y, et al.A rheostat for immune responses:the unique properties of PD-1 and their advantages for clinical application[J]. Nat Immunol, 2013, 14(12):1212-1218.
[49] TAO Y, LI P, FENG C, et al.New insights into immune cells and immunotherapy for thyroid cancer[J]. Immunol Invest, 2023, 52(8):1039-1064.
[50] GIANNINI R, MORETTI S, UGOLINI C, et al.Immune profiling of thyroid carcinomas suggests the existence of two major phenotypes:an ATC-like and a PDTC-like[J]. J Clin Endocrinol Metab, 2019, 104(8):3557-3575.
[51] 卢茜璇, 包黎莎, 潘宗富, 等.甲状腺未分化癌免疫治疗的现状及未来[J]. 浙江大学学报(医学版), 2021, 50(6):675-684.
[52] WANG K, ZHANG Y, XING Y, et al.Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials[J]. Discov Oncol, 2024, 15(1):50.
[53] TIAN Y, LI R, LIU Y, et al.The risk of immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients:an updated systematic review and meta-analysis[J]. Front Oncol, 2021, 11:667650.
[54] LONG B, BRÉM E, KOYFMAN A.Oncologic emergencies:immune-based cancer therapies and complications[J]. West J Emerg Med, 2020, 21(3):566-580.
[55] THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al.Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(4):387-405.
[56] GUNDA V, GIGLIOTTI B, ASHRY T, et al.Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer[J]. Int J Cancer, 2019, 144(9):2266-2278.
[57] BRAUNER E, GUNDA V, VANDEN BORRE P, et al.Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer[J]. Oncotarget, 2016, 7(13):17194-17211. |
